{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:14Z","timestamp":1793726054733,"version":"4.6.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602000"],"award-info":[{"award-number":["2022YFC3602000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0131700"],"award-info":[{"award-number":["2022YFE0131700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071813"],"award-info":[{"award-number":["82071813"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["Z191100006619114"],"award-info":[{"award-number":["Z191100006619114"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-024-03388-5","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T03:02:24Z","timestamp":1729566144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Ruiling","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3904-8928","authenticated-orcid":false,"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"issue":"10188","key":"3388_CR1","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332\u201343.","journal-title":"Lancet"},{"issue":"1","key":"3388_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, Liu J, Zhang X, Zhang X, Jin Y, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3388_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3388_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.scib.2022.12.024","volume":"68","author":"ZG Li","year":"2023","unstructured":"Li ZG, He J, Miao M. Low-dose interleukin-2 therapy in autoimmune and inflammatory diseases: facts and hopes. Sci Bull. 2023;68(1):10\u20133.","journal-title":"Sci Bull"},{"issue":"25","key":"3388_CR5","doi-asserted-by":"publisher","first-page":"eaat1482","DOI":"10.1126\/sciimmunol.aat1482","volume":"3","author":"AK Abbas","year":"2018","unstructured":"Abbas AK, Trotta E, Simeonov DR, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482.","journal-title":"Sci Immunol"},{"issue":"6","key":"3388_CR6","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.celrep.2022.111606","volume":"41","author":"C Guo","year":"2022","unstructured":"Guo C, Liu Q, Zong D, Zhang W, Zuo Z, Yu Q, Sha Q, Zhu L, Gao X, Fang J, et al. Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus. Cell Rep. 2022;41(6):111606.","journal-title":"Cell Rep"},{"issue":"12","key":"3388_CR7","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, Leroux D, Vazquez T, Riemekasten G, Smolen JS, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis. 2022;81(12):1685\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3388_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/BOR.0000000000000575","volume":"31","author":"JY Humrich","year":"2019","unstructured":"Humrich JY, Riemekasten G. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2019;31(2):208\u201312.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"3388_CR9","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3388_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang X, Miao M, Zhang R, Liu X, Zhao X, Shao M, Liu T, Jin Y, Chen J, Liu H, et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2022;7(1):67.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"3388_CR11","doi-asserted-by":"publisher","first-page":"e2241451","DOI":"10.1001\/jamanetworkopen.2022.41451","volume":"5","author":"J He","year":"2022","unstructured":"He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y, Feng R, Huang B, Luan H, Jia Y, et al. Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2241451.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3388_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","volume":"11","author":"KM Luijten","year":"2012","unstructured":"Luijten KM, Tekstra J, Bijlsma JW, Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev. 2012;11(5):326\u20139.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"3388_CR13","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3388_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991\u20133.","journal-title":"Nat Med"},{"issue":"10","key":"3388_CR15","doi-asserted-by":"publisher","first-page":"e1009858","DOI":"10.1371\/journal.ppat.1009858","volume":"17","author":"P Zhou","year":"2021","unstructured":"Zhou P, Chen J, He J, Zheng T, Yunis J, Makota V, Alexandre YO, Gong F, Zhang X, Xie W, et al. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. PLoS Pathog. 2021;17(10):e1009858.","journal-title":"PLoS Pathog"},{"issue":"Suppl 1","key":"3388_CR16","doi-asserted-by":"publisher","first-page":"i22","DOI":"10.1093\/rheumatology\/keac678","volume":"62","author":"J He","year":"2023","unstructured":"He J, Li Z. Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. Rheumatology (Oxford). 2023;62(Suppl 1):i22\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3388_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13075-021-02535-6","volume":"23","author":"M Miao","year":"2021","unstructured":"Miao M, Xiao X, Tian J, Zhufeng Y, Feng R, Zhang R, Chen J, Zhang X, Huang B, Jin Y, et al. Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. Arthritis Res Ther. 2021;23(1):167.","journal-title":"Arthritis Res Ther"},{"key":"3388_CR18","doi-asserted-by":"crossref","unstructured":"Miao M, Li Y, Xu D, Zhang R, He J, Sun X, Li Z. Therapeutic responses and predictors of low-dose interleukin-2 in systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40(5):867\u201371.","DOI":"10.21203\/rs.3.rs-138441\/v1"},{"issue":"7","key":"3388_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/ard.61.7.668","volume":"61","author":"AL Hepburn","year":"2002","unstructured":"Hepburn AL, Davies KA. Infection and SLE. Ann Rheum Dis. 2002;61(7):668\u20139; author reply 669.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3388_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/1744666X.2020.1763793","volume":"16","author":"MRW Barber","year":"2020","unstructured":"Barber MRW, Clarke AE. Systemic lupus erythematosus and risk of infection. Expert Rev Clin Immunol. 2020;16(5):527\u201338.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"3388_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00002281-200309000-00002","volume":"15","author":"I Kang","year":"2003","unstructured":"Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003;15(5):528\u201334.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"3388_CR22","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","volume":"63","author":"M Rosenzwajg","year":"2020","unstructured":"Rosenzwajg M, Salet R, Lorenzon R, Tchitchek N, Roux A, Bernard C, Carel JC, Storey C, Polak M, Beltrand J, et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I\/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia. 2020;63(9):1808\u201321.","journal-title":"Diabetologia"},{"key":"3388_CR23","doi-asserted-by":"publisher","first-page":"105912","DOI":"10.1016\/j.intimp.2019.105912","volume":"77","author":"M Feng","year":"2019","unstructured":"Feng M, Guo H, Zhang C, Wang Y, Liang Z, Zhao X, Qin Y, Wu Y, Liu G, Gao C, et al. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int Immunopharmacol. 2019;77:105912.","journal-title":"Int Immunopharmacol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03388-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T15:02:54Z","timestamp":1729609374000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03388-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethical committee of Peking University People\u2019s Hospital (approval number 2022PHB013-001) and all patients provided written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}